Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model

Imiquimod is an imidazoquinoline immune response modifier that is used in antiviral and antiallergic creams. Combination therapy using transcutaneous imiquimod and oral sorafenib was previously demonstrated to reduce the tumor burden of renal cell carcinoma growing cutaneously in a mouse model. In t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncol Lett
Autors principals: Karashima, Takashi, Udaka, Keiko, Niimura, Mayumi, Suzuki, Katsuhide, Osakabe, Hiroto, Shimamoto, Tsutomu, Fukata, Satoshi, Inoue, Keiji, Kuroda, Naoto, Seiki, Motoharu, Shuin, Taro
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2017
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5494610/
https://ncbi.nlm.nih.gov/pubmed/28693290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.6235
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars